Conceptus, Inc., creator of a new, non-surgical permanent contraceptive device for women announced phase II clinical results at the Annual Meeting of the International Society of Gynecological Endoscopy (ISGE). The meeting included a live case demonstration featuring the placement of the device without anesthesia, analgesia or noticeable patient discomfort.
STOP will begin marketing in Australia in early 2001. Conceptus has received permission to begin the next phase of trials in the United States.
The STOP device is a new hysteroscopic sterilization system. Tiny spring-like devices are implanted in the fallopian tubes. The fallopian tissues become irritated and grow over. Patients can discontinue contraceptive use three months after the procedure.
In preliminary tests, STOP has been 100% effective with more than 99% of patients rating tolerance to the procedure and device as "good to excellent." The entire procedure can be performed in about 20 minutes in the office setting without analgesia or anesthesia. Total time out of the patient's day is about 2-3 hours with a rapid return to the activities of daily living.
A visit to the Conceptus Inc. Web site at www.conceptus.com will provide answers to any question providers or patients might have. A patient FAQ on the device is very thorough and contains graphics. If you are patient, there is a video that can be downloaded.
If STOP clears the next few FDA hurdles it is sure to become one of the number one methods of contraception in the United States and possibly the world. Currently tubal ligation is the method of choice for most women. Tubal ligation requires anesthesia, is expensive and uncomfortable. The STOP procedure stands to revolutionize the field of contraception as it will give women a drug- and surgery-free option for permanent birth control.